<?xml version="1.0" encoding="UTF-8"?>
<p>Despite have fewer viral diagnoses, CHIKV infected patients were 4 times more likely to receive antiviral therapy (primarily acyclovir) than DENV patients (
 <xref rid="pntd.0008086.t003" ref-type="table">Table 3</xref>). While not significant, use of steroid therapy was documented in 5.1% of CHIKV patients as compared to 3.5% of patients with DENV (
 <xref rid="pntd.0008086.t003" ref-type="table">Table 3</xref>). Fluid replacement therapy was required in 76.6% of DENV patients and 51% of CHIKV infected patients (
 <xref rid="pntd.0008086.t003" ref-type="table">Table 3</xref>). Up to 60% of patients required analgesics in both groups (
 <xref rid="pntd.0008086.t003" ref-type="table">Table 3</xref>).
</p>
